{"transactions":[{"id":804657,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51958,"kind":"organization","name":"Illumina Innovation Fund II GP, L.L.C.","position":1,"cik":"0001779219","reported_name":"Illumina Innovation Fund II GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51959,"kind":"organization","name":"Illumina Innovation Fund II, L.P.","position":2,"cik":"0001779218","reported_name":"Illumina Innovation Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51960,"kind":"organization","name":"Illumina Innovation Fund III GP, L.L.C.","position":3,"cik":"0002032563","reported_name":"Illumina Innovation Fund III GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51961,"kind":"organization","name":"Illumina Innovation Fund III, L.P.","position":4,"cik":"0002032562","reported_name":"Illumina Innovation Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":5,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2026-04-21T00:45:36.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"price":0,"reported_value":3927259.98,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are held by Illumina Innovation Fund III, L.P. (\"IIF III\"). Illumina Innovation Fund III GP, L.L.C. (\"IIF III GP\") is the general partner of IIF III. Mr. Naclerio, a member of the Issuer's board of directors, is the sole managing member of IIF III GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF III. Each of IIF III GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF III, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":271782},"source":{"system":"sec-edgar","filing":"0001193125-26-164634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/2032562/000119312526164634/ownership.xml","form_type":"4"}},{"id":804656,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51958,"kind":"organization","name":"Illumina Innovation Fund II GP, L.L.C.","position":1,"cik":"0001779219","reported_name":"Illumina Innovation Fund II GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51959,"kind":"organization","name":"Illumina Innovation Fund II, L.P.","position":2,"cik":"0001779218","reported_name":"Illumina Innovation Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51960,"kind":"organization","name":"Illumina Innovation Fund III GP, L.L.C.","position":3,"cik":"0002032563","reported_name":"Illumina Innovation Fund III GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51961,"kind":"organization","name":"Illumina Innovation Fund III, L.P.","position":4,"cik":"0002032562","reported_name":"Illumina Innovation Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":5,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2026-04-21T00:45:36.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"price":0,"reported_value":5000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. Nicholas Naclerio (\"Mr. Naclerio\"), a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":346020},"source":{"system":"sec-edgar","filing":"0001193125-26-164634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/2032562/000119312526164634/ownership.xml","form_type":"4"}},{"id":804655,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51958,"kind":"organization","name":"Illumina Innovation Fund II GP, L.L.C.","position":1,"cik":"0001779219","reported_name":"Illumina Innovation Fund II GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51959,"kind":"organization","name":"Illumina Innovation Fund II, L.P.","position":2,"cik":"0001779218","reported_name":"Illumina Innovation Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51960,"kind":"organization","name":"Illumina Innovation Fund III GP, L.L.C.","position":3,"cik":"0002032563","reported_name":"Illumina Innovation Fund III GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51961,"kind":"organization","name":"Illumina Innovation Fund III, L.P.","position":4,"cik":"0002032562","reported_name":"Illumina Innovation Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":5,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2026-04-21T00:45:36.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":5037783,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1-for-2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1-for-2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1-for-2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. Nicholas Naclerio (\"Mr. Naclerio\"), a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":0,"derivative":{"underlying":"Class B Common Stock","underlying_shares":2083450},"source":{"system":"sec-edgar","filing":"0001193125-26-164634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/2032562/000119312526164634/ownership.xml","form_type":"4"}},{"id":804654,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51958,"kind":"organization","name":"Illumina Innovation Fund II GP, L.L.C.","position":1,"cik":"0001779219","reported_name":"Illumina Innovation Fund II GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51959,"kind":"organization","name":"Illumina Innovation Fund II, L.P.","position":2,"cik":"0001779218","reported_name":"Illumina Innovation Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51960,"kind":"organization","name":"Illumina Innovation Fund III GP, L.L.C.","position":3,"cik":"0002032563","reported_name":"Illumina Innovation Fund III GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51961,"kind":"organization","name":"Illumina Innovation Fund III, L.P.","position":4,"cik":"0002032562","reported_name":"Illumina Innovation Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":5,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-04-21T00:45:36.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":2094266,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1-for-2.271 basis and has no expiration date. The Series B Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1-for-2.271 basis and has no expiration date. The Series B Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1-for-2.271 basis and has no expiration date. The Series B Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. Nicholas Naclerio (\"Mr. Naclerio\"), a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":0,"derivative":{"underlying":"Class B Common Stock","underlying_shares":922152},"source":{"system":"sec-edgar","filing":"0001193125-26-164634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2032562/000119312526164634/ownership.xml","form_type":"4"}},{"id":804653,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51958,"kind":"organization","name":"Illumina Innovation Fund II GP, L.L.C.","position":1,"cik":"0001779219","reported_name":"Illumina Innovation Fund II GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51959,"kind":"organization","name":"Illumina Innovation Fund II, L.P.","position":2,"cik":"0001779218","reported_name":"Illumina Innovation Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51960,"kind":"organization","name":"Illumina Innovation Fund III GP, L.L.C.","position":3,"cik":"0002032563","reported_name":"Illumina Innovation Fund III GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51961,"kind":"organization","name":"Illumina Innovation Fund III, L.P.","position":4,"cik":"0002032562","reported_name":"Illumina Innovation Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":5,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-4 Preferred Stock","published_at":"2026-04-21T00:45:36.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":2862507,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1-for-2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1-for-2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1-for-2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. Nicholas Naclerio (\"Mr. Naclerio\"), a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":0,"derivative":{"underlying":"Class B Common Stock","underlying_shares":1183832},"source":{"system":"sec-edgar","filing":"0001193125-26-164634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2032562/000119312526164634/ownership.xml","form_type":"4"}},{"id":804652,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51958,"kind":"organization","name":"Illumina Innovation Fund II GP, L.L.C.","position":1,"cik":"0001779219","reported_name":"Illumina Innovation Fund II GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51959,"kind":"organization","name":"Illumina Innovation Fund II, L.P.","position":2,"cik":"0001779218","reported_name":"Illumina Innovation Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51960,"kind":"organization","name":"Illumina Innovation Fund III GP, L.L.C.","position":3,"cik":"0002032563","reported_name":"Illumina Innovation Fund III GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51961,"kind":"organization","name":"Illumina Innovation Fund III, L.P.","position":4,"cik":"0002032562","reported_name":"Illumina Innovation Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":5,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-3 Preferred Stock","published_at":"2026-04-21T00:45:36.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":3194377,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1-for-2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1-for-2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1-for-2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. Nicholas Naclerio (\"Mr. Naclerio\"), a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":0,"derivative":{"underlying":"Class B Common Stock","underlying_shares":1321082},"source":{"system":"sec-edgar","filing":"0001193125-26-164634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2032562/000119312526164634/ownership.xml","form_type":"4"}},{"id":804651,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51958,"kind":"organization","name":"Illumina Innovation Fund II GP, L.L.C.","position":1,"cik":"0001779219","reported_name":"Illumina Innovation Fund II GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51959,"kind":"organization","name":"Illumina Innovation Fund II, L.P.","position":2,"cik":"0001779218","reported_name":"Illumina Innovation Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51960,"kind":"organization","name":"Illumina Innovation Fund III GP, L.L.C.","position":3,"cik":"0002032563","reported_name":"Illumina Innovation Fund III GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51961,"kind":"organization","name":"Illumina Innovation Fund III, L.P.","position":4,"cik":"0002032562","reported_name":"Illumina Innovation Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":5,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-21T00:45:36.000Z","date":"2026-04-20","kind":"purchase","planned":false,"acquired":true,"shares":235294,"price":17,"value":3999998.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are held by Illumina Innovation Fund III, L.P. (\"IIF III\"). Illumina Innovation Fund III GP, L.L.C. (\"IIF III GP\") is the general partner of IIF III. Mr. Naclerio, a member of the Issuer's board of directors, is the sole managing member of IIF III GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF III. Each of IIF III GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF III, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":507076,"source":{"system":"sec-edgar","filing":"0001193125-26-164634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2032562/000119312526164634/ownership.xml","form_type":"4"}},{"id":804650,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51958,"kind":"organization","name":"Illumina Innovation Fund II GP, L.L.C.","position":1,"cik":"0001779219","reported_name":"Illumina Innovation Fund II GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51959,"kind":"organization","name":"Illumina Innovation Fund II, L.P.","position":2,"cik":"0001779218","reported_name":"Illumina Innovation Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51960,"kind":"organization","name":"Illumina Innovation Fund III GP, L.L.C.","position":3,"cik":"0002032563","reported_name":"Illumina Innovation Fund III GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51961,"kind":"organization","name":"Illumina Innovation Fund III, L.P.","position":4,"cik":"0002032562","reported_name":"Illumina Innovation Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":5,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-21T00:45:36.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":271782,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are held by Illumina Innovation Fund III, L.P. (\"IIF III\"). Illumina Innovation Fund III GP, L.L.C. (\"IIF III GP\") is the general partner of IIF III. Mr. Naclerio, a member of the Issuer's board of directors, is the sole managing member of IIF III GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF III. Each of IIF III GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF III, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":271782,"source":{"system":"sec-edgar","filing":"0001193125-26-164634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2032562/000119312526164634/ownership.xml","form_type":"4"}},{"id":804649,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51958,"kind":"organization","name":"Illumina Innovation Fund II GP, L.L.C.","position":1,"cik":"0001779219","reported_name":"Illumina Innovation Fund II GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51959,"kind":"organization","name":"Illumina Innovation Fund II, L.P.","position":2,"cik":"0001779218","reported_name":"Illumina Innovation Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51960,"kind":"organization","name":"Illumina Innovation Fund III GP, L.L.C.","position":3,"cik":"0002032563","reported_name":"Illumina Innovation Fund III GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51961,"kind":"organization","name":"Illumina Innovation Fund III, L.P.","position":4,"cik":"0002032562","reported_name":"Illumina Innovation Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":5,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-21T00:45:36.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":346020,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. Nicholas Naclerio (\"Mr. Naclerio\"), a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":5856536,"source":{"system":"sec-edgar","filing":"0001193125-26-164634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2032562/000119312526164634/ownership.xml","form_type":"4"}},{"id":804648,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51958,"kind":"organization","name":"Illumina Innovation Fund II GP, L.L.C.","position":1,"cik":"0001779219","reported_name":"Illumina Innovation Fund II GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51959,"kind":"organization","name":"Illumina Innovation Fund II, L.P.","position":2,"cik":"0001779218","reported_name":"Illumina Innovation Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51960,"kind":"organization","name":"Illumina Innovation Fund III GP, L.L.C.","position":3,"cik":"0002032563","reported_name":"Illumina Innovation Fund III GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51961,"kind":"organization","name":"Illumina Innovation Fund III, L.P.","position":4,"cik":"0002032562","reported_name":"Illumina Innovation Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":5,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-21T00:45:36.000Z","date":"2026-04-20","kind":"other","planned":false,"acquired":true,"shares":5510516,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. Nicholas Naclerio (\"Mr. Naclerio\"), a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":5510516,"source":{"system":"sec-edgar","filing":"0001193125-26-164634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2032562/000119312526164634/ownership.xml","form_type":"4"}},{"id":804647,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51958,"kind":"organization","name":"Illumina Innovation Fund II GP, L.L.C.","position":1,"cik":"0001779219","reported_name":"Illumina Innovation Fund II GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51959,"kind":"organization","name":"Illumina Innovation Fund II, L.P.","position":2,"cik":"0001779218","reported_name":"Illumina Innovation Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51960,"kind":"organization","name":"Illumina Innovation Fund III GP, L.L.C.","position":3,"cik":"0002032563","reported_name":"Illumina Innovation Fund III GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51961,"kind":"organization","name":"Illumina Innovation Fund III, L.P.","position":4,"cik":"0002032562","reported_name":"Illumina Innovation Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":5,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock","published_at":"2026-04-21T00:45:36.000Z","date":"2026-04-20","kind":"other","planned":false,"acquired":false,"shares":5510516,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. Nicholas Naclerio (\"Mr. Naclerio\"), a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-164634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2032562/000119312526164634/ownership.xml","form_type":"4"}},{"id":804646,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51958,"kind":"organization","name":"Illumina Innovation Fund II GP, L.L.C.","position":1,"cik":"0001779219","reported_name":"Illumina Innovation Fund II GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51959,"kind":"organization","name":"Illumina Innovation Fund II, L.P.","position":2,"cik":"0001779218","reported_name":"Illumina Innovation Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51960,"kind":"organization","name":"Illumina Innovation Fund III GP, L.L.C.","position":3,"cik":"0002032563","reported_name":"Illumina Innovation Fund III GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51961,"kind":"organization","name":"Illumina Innovation Fund III, L.P.","position":4,"cik":"0002032562","reported_name":"Illumina Innovation Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":5,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock","published_at":"2026-04-21T00:45:36.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":922152,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1-for-2.271 basis and has no expiration date. The Series B Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1-for-2.271 basis and has no expiration date. The Series B Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. Nicholas Naclerio (\"Mr. Naclerio\"), a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":5510516,"source":{"system":"sec-edgar","filing":"0001193125-26-164634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2032562/000119312526164634/ownership.xml","form_type":"4"}},{"id":804645,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51958,"kind":"organization","name":"Illumina Innovation Fund II GP, L.L.C.","position":1,"cik":"0001779219","reported_name":"Illumina Innovation Fund II GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51959,"kind":"organization","name":"Illumina Innovation Fund II, L.P.","position":2,"cik":"0001779218","reported_name":"Illumina Innovation Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51960,"kind":"organization","name":"Illumina Innovation Fund III GP, L.L.C.","position":3,"cik":"0002032563","reported_name":"Illumina Innovation Fund III GP, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51961,"kind":"organization","name":"Illumina Innovation Fund III, L.P.","position":4,"cik":"0002032562","reported_name":"Illumina Innovation Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":5,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock","published_at":"2026-04-21T00:45:36.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":4588364,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1-for-2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1-for-2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. Nicholas Naclerio (\"Mr. Naclerio\"), a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":4588364,"source":{"system":"sec-edgar","filing":"0001193125-26-164634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032562/000119312526164634/ownership.xml","form_type":"4"}},{"id":804321,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":1,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Promissory Note","published_at":"2026-04-21T00:31:47.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"price":0,"reported_value":3927259.98,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are held by Illumina Innovation Fund III, L.P. (\"IIF III\"). Illumina Innovation Fund III GP, L.L.C. (\"IIF II GP\") is the general partner of IIF III. The reporting person, a member of the Issuer's board of directors, is the sole managing member of IIF III GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF III. Each of IIF III GP and the reporting person disclaim beneficial ownership over the securities held by IIF III, except to the extent of their respective pecuniary\ninterests therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":271782},"source":{"system":"sec-edgar","filing":"0001534166-26-000006","document":"form4-04212026_120442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1534166/000153416626000006/form4-04212026_120442.xml","form_type":"4"}},{"id":804320,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":1,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Promissory Note","published_at":"2026-04-21T00:31:47.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"price":0,"reported_value":5000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. The reporting person, a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and the reporting person disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary\ninterests therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":346020},"source":{"system":"sec-edgar","filing":"0001534166-26-000006","document":"form4-04212026_120442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1534166/000153416626000006/form4-04212026_120442.xml","form_type":"4"}},{"id":804319,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":1,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2026-04-21T00:31:47.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":5037783,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1:2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1:2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1:2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. The reporting person, a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and the reporting person disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary\ninterests therein, if any."}],"balance_after":0,"derivative":{"underlying":"Class B Common Stock","underlying_shares":2083450},"source":{"system":"sec-edgar","filing":"0001534166-26-000006","document":"form4-04212026_120442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1534166/000153416626000006/form4-04212026_120442.xml","form_type":"4"}},{"id":804318,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":1,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-04-21T00:31:47.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":2094266,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.271 basis and has no expiration date. The Series B Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.271 basis and has no expiration date. The Series B Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.271 basis and has no expiration date. The Series B Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. The reporting person, a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and the reporting person disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary\ninterests therein, if any."}],"balance_after":0,"derivative":{"underlying":"Class B Common Stock","underlying_shares":922152},"source":{"system":"sec-edgar","filing":"0001534166-26-000006","document":"form4-04212026_120442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1534166/000153416626000006/form4-04212026_120442.xml","form_type":"4"}},{"id":804317,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":1,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-4 Preferred Stock","published_at":"2026-04-21T00:31:47.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":2862507,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1:2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1:2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1:2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. The reporting person, a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and the reporting person disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary\ninterests therein, if any."}],"balance_after":0,"derivative":{"underlying":"Class B Common Stock","underlying_shares":1183832},"source":{"system":"sec-edgar","filing":"0001534166-26-000006","document":"form4-04212026_120442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1534166/000153416626000006/form4-04212026_120442.xml","form_type":"4"}},{"id":804316,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":1,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-3 Preferred Stock","published_at":"2026-04-21T00:31:47.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":3194377,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1:2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1:2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1:2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. The reporting person, a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and the reporting person disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary\ninterests therein, if any."}],"balance_after":0,"derivative":{"underlying":"Class B Common Stock","underlying_shares":1321082},"source":{"system":"sec-edgar","filing":"0001534166-26-000006","document":"form4-04212026_120442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1534166/000153416626000006/form4-04212026_120442.xml","form_type":"4"}},{"id":804315,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":1,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-21T00:31:47.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":25599,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"One-third of the shares subject to the grant will vest on April 16, 2027 and the remainder of the shares subject to the grant will vest in equal monthly installments thereafter through April 16, 2029, subject to the reporting person's continuous service through each such vesting date."}],"balance_after":25599,"derivative":{"exercise_price":17,"expiration_date":"2036-04-15","underlying":"Common Stock","underlying_shares":25599},"source":{"system":"sec-edgar","filing":"0001534166-26-000006","document":"form4-04212026_120442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1534166/000153416626000006/form4-04212026_120442.xml","form_type":"4"}},{"id":804314,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":1,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-21T00:31:47.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":5686,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents the grant of restricted stock units (\"RSUs\"). The RSUs vest 1/3rd on each of April 20, 2027, April 20, 2028 and April 20, 2029, subject to the reporting person's continuous service as of each such vesting date."}],"balance_after":5686,"source":{"system":"sec-edgar","filing":"0001534166-26-000006","document":"form4-04212026_120442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1534166/000153416626000006/form4-04212026_120442.xml","form_type":"4"}},{"id":804313,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":1,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-21T00:31:47.000Z","date":"2026-04-20","kind":"purchase","planned":false,"acquired":true,"shares":235294,"price":17,"value":3999998.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are held by Illumina Innovation Fund III, L.P. (\"IIF III\"). Illumina Innovation Fund III GP, L.L.C. (\"IIF II GP\") is the general partner of IIF III. The reporting person, a member of the Issuer's board of directors, is the sole managing member of IIF III GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF III. Each of IIF III GP and the reporting person disclaim beneficial ownership over the securities held by IIF III, except to the extent of their respective pecuniary\ninterests therein, if any."}],"balance_after":507076,"source":{"system":"sec-edgar","filing":"0001534166-26-000006","document":"form4-04212026_120442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1534166/000153416626000006/form4-04212026_120442.xml","form_type":"4"}},{"id":804312,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":1,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-21T00:31:47.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":271782,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are held by Illumina Innovation Fund III, L.P. (\"IIF III\"). Illumina Innovation Fund III GP, L.L.C. (\"IIF II GP\") is the general partner of IIF III. The reporting person, a member of the Issuer's board of directors, is the sole managing member of IIF III GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF III. Each of IIF III GP and the reporting person disclaim beneficial ownership over the securities held by IIF III, except to the extent of their respective pecuniary\ninterests therein, if any."}],"balance_after":271782,"source":{"system":"sec-edgar","filing":"0001534166-26-000006","document":"form4-04212026_120442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1534166/000153416626000006/form4-04212026_120442.xml","form_type":"4"}},{"id":804311,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":1,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-21T00:31:47.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":346020,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. The reporting person, a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and the reporting person disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary\ninterests therein, if any."}],"balance_after":5856536,"source":{"system":"sec-edgar","filing":"0001534166-26-000006","document":"form4-04212026_120442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1534166/000153416626000006/form4-04212026_120442.xml","form_type":"4"}},{"id":804310,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":1,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-21T00:31:47.000Z","date":"2026-04-20","kind":"other","planned":false,"acquired":true,"shares":5510516,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. The reporting person, a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and the reporting person disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary\ninterests therein, if any."}],"balance_after":5510516,"source":{"system":"sec-edgar","filing":"0001534166-26-000006","document":"form4-04212026_120442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1534166/000153416626000006/form4-04212026_120442.xml","form_type":"4"}},{"id":804309,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":1,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock","published_at":"2026-04-21T00:31:47.000Z","date":"2026-04-20","kind":"other","planned":false,"acquired":false,"shares":5510516,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. The reporting person, a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and the reporting person disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary\ninterests therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001534166-26-000006","document":"form4-04212026_120442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534166/000153416626000006/form4-04212026_120442.xml","form_type":"4"}},{"id":804308,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":1,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock","published_at":"2026-04-21T00:31:47.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":922152,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.271 basis and has no expiration date. The Series B Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.271 basis and has no expiration date. The Series B Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. The reporting person, a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and the reporting person disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary\ninterests therein, if any."}],"balance_after":5510516,"source":{"system":"sec-edgar","filing":"0001534166-26-000006","document":"form4-04212026_120442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534166/000153416626000006/form4-04212026_120442.xml","form_type":"4"}},{"id":804307,"issuer":{"id":1791,"kind":"organization","name":"Alamar Biosciences, Inc.","symbol":"ALMR"},"owners":[{"id":51914,"kind":"person","name":"Naclerio Nicholas","position":1,"cik":"0001534166","reported_name":"Naclerio Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock","published_at":"2026-04-21T00:31:47.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":4588364,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1:2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1:2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Illumina Innovation Fund II, L.P. (\"IIF II\"). Illumina Innovation Fund II GP, L.L.C. (\"IIF II GP\") is the general partner of IIF II. The reporting person, a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and the reporting person disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary\ninterests therein, if any."}],"balance_after":4588364,"source":{"system":"sec-edgar","filing":"0001534166-26-000006","document":"form4-04212026_120442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534166/000153416626000006/form4-04212026_120442.xml","form_type":"4"}}]}